These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33229626)

  • 1. Steroid 5 alpha-reductase 3 (SRD5A3) promotes tumor growth and predicts poor survival of human hepatocellular carcinoma (HCC).
    Mai Q; Sheng D; Chen C; Gou Q; Chen M; Huang X; Yin H; Chen X; Chen Z
    Aging (Albany NY); 2020 Nov; 12(24):25395-25411. PubMed ID: 33229626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the implication of steroid 5 alpha-reductase 3 on prognosis and immune microenvironment in Liver Hepatocellular Carcinoma.
    Lu Y; Liu Z; Zheng Y; Liu X; Liu X; Chen N; Mao K; Lin W
    Ann Med; 2024 Dec; 56(1):2408463. PubMed ID: 39340288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo.
    Zhou L; Wang Z; Xu X; Wan Y; Qu K; Fan H; Chen Q; Sun X; Liu C
    Oncotarget; 2016 Apr; 7(14):18620-30. PubMed ID: 26921196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
    Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canopy Homolog 2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma with Tumor Hemorrhage.
    Wang D; Wang ZM; Zhang S; Wu HJ; Tao YM
    Cell Physiol Biochem; 2018; 50(6):2017-2028. PubMed ID: 30415246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of SRD5A3 in Hepatocellular Carcinoma and Its Molecular Mechanism: A Study of Bioinformatics Exploration Analysis with Experimental Verification.
    Chen E; Yi J; Ren Q; Mi Y; Gan Z; Liu J
    Evid Based Complement Alternat Med; 2022; 2022():7853168. PubMed ID: 36159555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4.
    Zhao Y; Li F; Zhang X; Liu A; Qi J; Cui H; Zhao P
    Int J Clin Exp Pathol; 2015; 8(10):12446-54. PubMed ID: 26722431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma.
    Zheng H; Jiang WH; Tian T; Tan HS; Chen Y; Qiao GL; Han J; Huang SY; Yang Y; Li S; Wang ZG; Gao R; Ren H; Xing H; Ni JS; Wang LH; Ma LJ; Zhou WP
    Oncotarget; 2017 Mar; 8(12):18872-18884. PubMed ID: 28122351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma.
    Zhang HX; Jiang SS; Zhang XF; Zhou ZQ; Pan QZ; Chen CL; Zhao JJ; Tang Y; Xia JC; Weng DS
    Oncotarget; 2015 Oct; 6(33):34800-17. PubMed ID: 26430962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma.
    Zhong X; Kan A; Zhang W; Zhou J; Zhang H; Chen J; Tang S
    Aging (Albany NY); 2019 Aug; 11(15):5483-5497. PubMed ID: 31375643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study.
    Wang Y; Huang Q; Deng T; Li BH; Ren XQ
    Med Sci Monit; 2019 May; 25():3894-3901. PubMed ID: 31128068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
    Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
    Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
    Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
    Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma.
    Lv X; Zhao F; Huo X; Tang W; Hu B; Gong X; Yang J; Shen Q; Qin W
    Med Oncol; 2016 Jul; 33(7):70. PubMed ID: 27262566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
    Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
    Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma.
    Lyu Z; Ma M; Xu Y; Wang X; Zhu Y; Ren W; Li T
    Int J Clin Oncol; 2020 Jul; 25(7):1334-1345. PubMed ID: 32347431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA PCAT6 predicts poor prognosis in hepatocellular carcinoma and promotes proliferation through the regulation of cell cycle arrest and apoptosis.
    Luo Y; Lin J; Zhang Y; Dai G; Li A; Liu X
    Cell Biochem Funct; 2020 Oct; 38(7):895-904. PubMed ID: 32064636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma.
    Zhang S; Zhang K; Ji P; Zheng X; Jin J; Feng M; Liu P
    BMC Cancer; 2017 May; 17(1):380. PubMed ID: 28549418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
    Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
    BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIP6 promotes tumorigenic capability through regulating FOXC1 in hepatocellular carcinoma.
    Wang F; Zhang B; Xu X; Zhu L; Zhu X
    Pathol Res Pract; 2020 Apr; 216(4):152850. PubMed ID: 32046874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.